ISSN: 1837-9664Journal of Cancer
Global reach, higher impact
J Cancer 2020; 11(7):1940-1948. doi:10.7150/jca.37003 This issue Cite
Research Paper
Development and validation of a 4-gene combination for the prognostication in lung adenocarcinoma patients
1. Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei province, China
2. Wuhan University School of Health Sciences, Wuhan, Hubei province, China
3. Department of Epidemiology, Department of Epidemiology, School of Health Sciences, Wuhan University, Wuhan, Hubei, China
4. Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei province, China
Citation:
Yin XH, Yu LP, Zhao XH, Li QM, Liu XP, He L. Development and validation of a 4-gene combination for the prognostication in lung adenocarcinoma patients. J Cancer 2020; 11(7):1940-1948. doi:10.7150/jca.37003. https://www.jcancer.org/v11p1940.htm
Other stylesAbstract
Objective: To identify a multi-gene prognostic factor in patients with lung adenocarcinoma (LUAD).
Materials and methods Prognosis-related genes were screened in the TCGA-LUAD cohort. Then, patients in this cohort were randomly separated into training set and test set. Least absolute shrinkage and selection operator (LASSO) regression was performed to the penalized the Cox proportional hazards regression (CPH) model on the training set, and a prognostication combination based on the result of LASSO analysis was developed. By performing Kaplan-Meier curve analysis, univariate and multivariable CPH model on the overall survival (OS) as well as recurrence free survival (RFS), the prognostication performance of the multigene combination were evaluated. Moreover, we constructed a nomogram and performed decision curve analysis to evaluate the clinical application of the multigene combination.
Results We obtained 99 prognosis-related genes and screened out a 4-gene combination (including CIDEC, ZFP3, DKK1, and USP4) according to the LASSO analysis. The results of survival analyses suggested that patients in the 4-gene combination low-risk group had better OS and RFS than those in the 4-gene combination high-risk group. The 4-gene mentioned was demonstrated to be independent prognostic factor of patients with LUAD in the training set(OS, HR=11.962, P<0.001; RFS, HR=9.281, P<0.001) and test set (OS, HR=5.377, P=0.003; RFS, HR=2.949, P=0.104). More importantly, its prognosis performance was well in the validation set (OS, HR=0.955, P=0.002; RFS, HR=1.042, P<0.001).
Conclusions We introduced a 4-gene combination which could predict the survival of LUAD patients and might be an independent prognostic factor in LUAD.
Keywords: lung adenocarcinoma, prognostication, least absolute shrinkage and selection operator, survival analysis
Citation styles
APA
Yin, X.H., Yu, L.P., Zhao, X.H., Li, Q.M., Liu, X.P., He, L. (2020). Development and validation of a 4-gene combination for the prognostication in lung adenocarcinoma patients. Journal of Cancer, 11(7), 1940-1948. https://doi.org/10.7150/jca.37003.
ACS
Yin, X.H.; Yu, L.P.; Zhao, X.H.; Li, Q.M.; Liu, X.P.; He, L. Development and validation of a 4-gene combination for the prognostication in lung adenocarcinoma patients. J. Cancer 2020, 11 (7), 1940-1948. DOI: 10.7150/jca.37003.
NLM
Yin XH, Yu LP, Zhao XH, Li QM, Liu XP, He L. Development and validation of a 4-gene combination for the prognostication in lung adenocarcinoma patients. J Cancer 2020; 11(7):1940-1948. doi:10.7150/jca.37003. https://www.jcancer.org/v11p1940.htm
CSE
Yin XH, Yu LP, Zhao XH, Li QM, Liu XP, He L. 2020. Development and validation of a 4-gene combination for the prognostication in lung adenocarcinoma patients. J Cancer. 11(7):1940-1948.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.